A review of 11 years of Stenotrophomonas maltophilia blood isolates at a tertiary care institute in Canada

Canadian Journal of Infectious Diseases and Medical Microbiology

Volumn 23, Issue 4, 2012, Pages 165-169

  Naidu, Prenilla ^a   Smith, Stephanie ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Bloodstream infections; Catheter related infections; Stenotrophomonas

Indexed keywords

COTRIMOXAZOLE; DOXYCYCLINE; MINOCYCLINE; TETRACYCLINE; TIMENTIN;

ADULT; AGED; ANTIBIOTIC SENSITIVITY; BACTEREMIA; BACTERIUM ISOLATE; BLOODSTREAM INFECTION; CANADA; CAUSE OF DEATH; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL STUDY; DEMOGRAPHY; FEMALE; GRAM NEGATIVE INFECTION; HUMAN; INTENSIVE CARE UNIT; LENGTH OF STAY; MALE; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; REVIEW; SEPSIS; STENOTROPHOMONAS MALTOPHILIA; STENOTROPHOMONAS MALTOPHILIA BLOODSTREAM INFECTION; TERTIARY HEALTH CARE;

EID: 84872788565     PISSN: 17129532     EISSN: None     Source Type: Journal    
DOI: 10.1155/2012/762571     Document Type: Review

References (22)

1. Spencer RC. The emergence of epidemic, multiple-antibiotic-resistant Stenotrophomonas maltophilia and Burkholderia cepacia. J Hosp Infect 1995;30:453-64.
2. Barchitta M, Cipresso R, Giaquinta L, et al. Acquisition and spread of Acinetobacter baumannii and Stenotrophomonas maltophilia in intensive care patients. Int J Hyg Environ Health 2009;212:330-7.
3. Nyc O, Matejkova J. Stenotrophomonas maltophilia: Significant contemporary hospital pathogen - review. Folia Microbiol 2010;55:286-94.
4. Centers for Disease Prevention and Control. National Hospital Surveillance Network website. (Accessed November 30, 2010).
5. Looney WJ, Narita M, Muhlemann K. Stenotrophomonas maltophilia: An emerging opportunist human pathogen. Lancet Infect Dis 2009;9:312-23.
6. Micozz1 A, Venditti M, Monaco M, et al. Bacteremia due to Stenotrophomonas maltophilia in patients with haematologic malignancies. Clin Infect Dis 2000;31:705-11.
7. Gales AC, Jones RN, Forward KR, Linares, J, Sader HS, Verhoef J. Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: Geographic patterns, epidemiological features, and trends in the SENTRY Antimicrobial Surveillance Program (1997-1999). Clin Infect Dis 2001;32(Suppl 2):S104-13.
8. Tan CK, Liaw SJ, Yu CJ, Teng LJ, Hsueh PR. Extensively drug resistant Stenotrophomonas maltophilia in a tertiary care hospital in Taiwan: Microbiologic characteristics, clinical features, and outcomes. Diag Microbiol Infect Dis 2008;60:205-10.
9. Rolston KVI, Elting L, Waguespack S, Ho DH, LeBlanc B, Bodey G P. Survey of antibiotic susceptibility among gram-negative bacilli at a cancer center. Chemotherapy 1996;42:348-53.
10. Safdar A, Rolston KV. Stenotrophomonas maltophilia: Changing spectrum of a serious bacterial pathogen in patients with cancer. Clin Infect Dis 2007;45:1602-09.
11. Garcia Paez JI, Costa SF. Risk factors associated with mortality of infections caused by Stenotrophomonas maltophilia: A systematic review. J Hosp Infect 2008;70:101-8.
12. Chaplow R, Palmer B, Heyderman R, Moppet J. Stenotrophomonas maltophilia bacteraemia in 40 haematological patients: Risk factors, therapy and outcome. Bone Marrow Transplant 2010;45:1109-10.
13. Lai CH, Wong WW, Chin C, et al. Central venous catheter-related Stenotrophomonas maltophilia bacteremia and associated relapsing bacteremia in haematology and oncology patients. Clin Microbiol Infect 2006;12:986-91.
14. Fouhy Y, Scanlon K, Schouest K, et al. Diffusible signal factor dependent cell-cell signaling and virulence in the nosocomial pathogen Stenotrophomonas maltophilia. J Bacteriol 2007;189:4964-8.
15. Garcia Paez JI, Tengan FM, Barone AA, Levin AS, Costa SF. Factors associated with mortality in patients with bloodstream infection and pneumonia due to Stenotrophomonas maltophilia. Eur J Clin Microbiol Infect Dis 2008;27:901-6.
16. Clinical and Laboratory Standards Institute. 2010. Performance standards for antimicrobial susceptibility testing; twentieth informational supplement. M100 - S20;v30(1):29.
17. Clinical breakpoints - bacteria (v1.3). European Committee on Antimicrobial Susceptibility Testing (EUCAST). Published 2010. (Accessed December 20, 2010).
18. Standardized Disc Susceptibility Testing. British Society for Antimicrobial Chemotherapy (BSAC). (Accessed December 20, 2010).
19. Sader HS, Jones RN. Antimicrobial susceptibility of uncommonly isolated non-enteric gram-negative bacilli. Int J Antimicrob Agents 2005;25:95-109.
20. Lai CH, Chi CY, Chen H P, et al. Clinical characteristics and prognostic factors of patients with Stenotrophomonas maltophilia bacteremia. J Microbiol Immunol Infect 2004;37:350-8.
21. Valdezate S, Vindel A, Loza E, Baquero F, Cantón R. Antimicrobial susceptibilities of unique Stenotrophomonas maltophilia clinical strains. Antimicrob Agents Chemoth 2001;45:1581-4.
22. Güriz H, Ciftçi E, Ayberkin E, et al. Stenotrophomonas maltophilia bacteraemia in Turkish children. Ann Trop Paediatr 2008;28:129-36.